Is pandrug-resistance in A. baumannii a transient phenotype? Epidemiological clues from a 4-year cohort study at a tertiary referral hospital in Greece

References

• Karakonstantis S, Saridakis I. Colistin heteroresistance in Acinetobacter spp; systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int J Antimicrob Agents. 2020;56(2):106065.
   PubMed Web of Science ®Google Scholar
• Karakonstantis S. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in acinetobacter baumannii. J Chemother. 2020. doi: https://doi.org/10.1080/1120009X.2020.1794393
   Google Scholar
• McGann P, Courvalin P, Snesrud E, Clifford RJ, Yoon E-J, Onmus-Leone F, Ong AC, Kwak YI, Grillot-Courvalin C, Lesho E, et al. Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure. mBio. 2014;5(2):e00915.
   PubMed Web of Science ®Google Scholar
• Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2019;75(2):271–82.
   Web of Science ®Google Scholar
• Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17(8):479–96.
   PubMed Web of Science ®Google Scholar
• Da Silva GJ, Domingues S. Interplay between colistin resistance, virulence and fitness in acinetobacter baumannii. Antibiotics (Basel). 2017;6(4):28.
   Web of Science ®Google Scholar
• Snitkin ES, Zelazny AM, Gupta J, Palmore TN, Murray PR, Segre JA, NISC Comparative Sequencing Program. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res. 2013;23(7):1155–62.
   PubMed Web of Science ®Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
   PubMed Web of Science ®Google Scholar
• Rumbo C, Gato E, López M, Ruiz de Alegría C, Fernández-Cuenca F, Martínez-Martínez L, Vila J, Pachón J, Cisneros JM, Rodríguez-Baño J, Spanish Network for Research in Infectious Diseases(REIPI), et al. Contribution of efflux pumps, porins, and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57(11):5247–57.
   PubMed Web of Science ®Google Scholar
• Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother. 2011;55(3):947–53.
   PubMed Web of Science ®Google Scholar
• Satılmış Ş, Hasdemir U, Aksu B, Altınkanat Gelmez G, Söyletir G. Alterations in AdeS and AdeR regulatory proteins in 1-(1-naphthylmethyl)-piperazine responsive colistin resistance of Acinetobacter baumannii. J Chemother. 2020;32(6): 286–293. doi: https://doi.org/10.1080/1120009X.2020.1735118.
   PubMed Web of Science ®Google Scholar
• Tsioutis C, Kritsotakis EI, Karageorgos SA, Stratakou S, Psarologakis C, Kokkini S, Gikas A. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents. 2016;48(5):492–7.
   PubMed Web of Science ®Google Scholar
• Kofteridis DP, Andrianaki AM, Maraki S, Mathioudaki A, Plataki M, Alexopoulou C, Ioannou P, Samonis G, Valachis A. Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2020;39(5):965–70.
   PubMed Web of Science ®Google Scholar
• Karakonstantis S, Gikas A, Astrinaki E, Kritsotakis EI. Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients. J Hosp Infect. 2020. doi: https://doi.org/10.1016/j.jhin.2020.09.009
   Google Scholar
• Karakonstantis S, Kritsotakis E, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii Co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline. An approach based on the mechanisms of resistance to carbapenems. Infection. 2020. doi: https://doi.org/10.1007/s15010-020-01520-6
   Google Scholar
• Wong FH, Cai Y, Leck H, Lim TP, Teo JQ, Lee W, et al. Determining the development of persisters in extensively drug-resistant Acinetobacter baumannii upon exposure to Polymyxin B-Based antibiotic combinations using flow cytometry. Antimicrob Agents Chemother. 2020;64(3):e01712-19. doi: https://doi.org/10.1128/AAC.01712-19.
   Google Scholar
• Girardello R, Cury AP, Franco MRG, Di Gióia TR, de Almeida JN, de Araújo MRE, da Silva Duarte AJ, Rossi F. Colistin susceptibility testing and Vitek-2™: is it really useless? Diagn Microbiol Infect Dis. 2018;91(4):309–11.
   PubMed Web of Science ®Google Scholar
• Singhal L, Sharma M, Verma S, Kaur R, Britto XB, Kumar SM, et al. Comparative evaluation of broth microdilution with polystyrene and glass-coated plates, agar dilution, E-Test, vitek, and disk diffusion for susceptibility testing of colistin and Polymyxin B on carbapenem-resistant clinical isolates of Acinetobacter baumannii. Microb Drug Resist. 2018;24(8):1082–1088. doi: https://doi.org/10.1089/mdr.2017.0251.
   PubMed Web of Science ®Google Scholar
• Lo-Ten-Foe JR, de Smet AMGA, Diederen BMW, Kluytmans JAJW, van Keulen PHJ. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob Agents Chemother. 2007;51(10):3726–30.
   PubMed Web of Science ®Google Scholar
• Rodriguez CH, Traglia G, Bastias N, Pandolfo C, Bruni G, Nastro M, Barrios R, Bavastro EM, Rey MC, Marques IA, et al. Discrepancies in susceptibility testing to colistin in Acinetobacter baumannii: The influence of slow growth and heteroresistance. Int J Antimicrob Agents. 2019;54(5):587–91.
   PubMed Web of Science ®Google Scholar